119 related articles for article (PubMed ID: 30263099)
1. Apatinib-based targeted therapy against pulmonary sarcomatoid carcinoma: a case report and literature review.
Li X; He Y; Zhu J; Pang H; Lin Y; Zheng J
Oncotarget; 2018 Sep; 9(72):33734-33738. PubMed ID: 30263099
[TBL] [Abstract][Full Text] [Related]
2. Apatinib as targeted therapy for sarcoma.
Li F; Liao Z; Zhang C; Zhao J; Xing R; Teng S; Zhang J; Yang Y; Yang J
Oncotarget; 2018 May; 9(36):24548-24560. PubMed ID: 29849960
[TBL] [Abstract][Full Text] [Related]
3. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
Li F; Zhu T; Cao B; Wang J; Liang L
Eur J Cancer; 2017 Oct; 84():184-192. PubMed ID: 28822888
[TBL] [Abstract][Full Text] [Related]
4. Significant efficacy and well safety of apatinib in an advanced liver cancer patient: a case report and literature review.
Kou P; Zhang Y; Shao W; Zhu H; Zhang J; Wang H; Kong L; Yu J
Oncotarget; 2017 Mar; 8(12):20510-20515. PubMed ID: 28103584
[TBL] [Abstract][Full Text] [Related]
5. Apatinib treatment in extensive metastatic advanced thymic carcinoma.
He Y; Liu S; E M; Wang C; Shi M; Liu G; Abiyasi N
J Biol Regul Homeost Agents; 2018; 32(3):693-697. PubMed ID: 29921401
[TBL] [Abstract][Full Text] [Related]
6. Response to apatinib in chemotherapy-failed advanced spindle cell breast carcinoma.
Zhou N; Liu C; Hou H; Zhang C; Liu D; Wang G; Liu K; Zhu J; Lv H; Li T; Zhang X
Oncotarget; 2016 Nov; 7(44):72373-72379. PubMed ID: 27738308
[TBL] [Abstract][Full Text] [Related]
7. Apatinib combined with concurrent chemoradiotherapy in patients with subglottic small cell carcinoma: a case report.
Chen M; Wu S; He Z; Cheng Z; Duan S; Jiang H; Wang G
J Int Med Res; 2021 May; 49(5):3000605211016146. PubMed ID: 34038201
[TBL] [Abstract][Full Text] [Related]
8. Rapid response of locally advanced oral squamous cell carcinoma to apatinib: A case report.
He J; Zhang Y; Gao J; Qian L
Open Med (Wars); 2021; 16(1):1668-1672. PubMed ID: 34761117
[TBL] [Abstract][Full Text] [Related]
9. Successful treatment of angiosarcoma of the scalp with apatinib: a case report.
Ji G; Hong L; Yang P
Onco Targets Ther; 2016; 9():4989-92. PubMed ID: 27563253
[TBL] [Abstract][Full Text] [Related]
10. Case Report: Favorable Response to the Tyrosine Kinase Inhibitor Apatinib in Recurrent Merkel Cell Carcinoma.
Feng Y; Song X; Jia R
Front Oncol; 2021; 11():625360. PubMed ID: 33747940
[TBL] [Abstract][Full Text] [Related]
11. Advanced alveolar soft part sarcoma responds to apatinib.
Zhou Y; Tang F; Wang Y; Min L; Luo Y; Zhang W; Shi R; Duan H; Tu C
Oncotarget; 2017 Jul; 8(30):50314-50322. PubMed ID: 28679123
[TBL] [Abstract][Full Text] [Related]
12. Sarcomatoid carcinoma of the lung presenting as a cutaneous metastasis.
Terada T
J Cutan Pathol; 2010 Apr; 37(4):482-5. PubMed ID: 19602061
[TBL] [Abstract][Full Text] [Related]
13. Apatinib for molecular targeted therapy in tumor.
Zhang H
Drug Des Devel Ther; 2015; 9():6075-81. PubMed ID: 26622168
[TBL] [Abstract][Full Text] [Related]
14. Genomic Characterization of Renal Cell Carcinoma with Sarcomatoid Dedifferentiation Pinpoints Recurrent Genomic Alterations.
Malouf GG; Ali SM; Wang K; Balasubramanian S; Ross JS; Miller VA; Stephens PJ; Khayat D; Pal SK; Su X; Sircar K; Tamboli P; Jonasch E; Tannir NM; Wood CG; Karam JA
Eur Urol; 2016 Aug; 70(2):348-57. PubMed ID: 26895810
[TBL] [Abstract][Full Text] [Related]
15. Apatinib inhibits VEGFR-2 and angiogenesis in an
Peng QX; Han YW; Zhang YL; Hu J; Fan J; Fu SZ; Xu S; Wan Q
Oncotarget; 2017 Aug; 8(32):52813-52822. PubMed ID: 28881773
[TBL] [Abstract][Full Text] [Related]
16. Apatinib, an Inhibitor of Vascular Endothelial Growth Factor Receptor 2, Suppresses Pathologic Ocular Neovascularization in Mice.
Kim KL; Suh W
Invest Ophthalmol Vis Sci; 2017 Jul; 58(9):3592-3599. PubMed ID: 28715845
[TBL] [Abstract][Full Text] [Related]
17. Apatinib: A novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer.
Roviello G; Ravelli A; Polom K; Petrioli R; Marano L; Marrelli D; Roviello F; Generali D
Cancer Lett; 2016 Mar; 372(2):187-91. PubMed ID: 26797419
[TBL] [Abstract][Full Text] [Related]
18. Novel role of apatinib as a multi-target RTK inhibitor in the direct suppression of hepatocellular carcinoma cells.
Li X; Xu A; Li H; Zhang B; Cao B; Huang J
Biochim Biophys Acta Mol Basis Dis; 2018 May; 1864(5 Pt A):1693-1701. PubMed ID: 29486282
[TBL] [Abstract][Full Text] [Related]
19. Apatinib as an alternative therapy for advanced hepatocellular carcinoma.
Zhang XH; Cao MQ; Li XX; Zhang T
World J Hepatol; 2020 Oct; 12(10):766-774. PubMed ID: 33200015
[TBL] [Abstract][Full Text] [Related]
20. Apatinib for metastatic breast cancer in non-clinical trial setting: Satisfying efficacy regardless of previous anti-angiogenic treatment.
Lin Y; Wu Z; Zhang J; Hu X; Wang Z; Wang B; Cao J; Wang L
Tumour Biol; 2017 Jun; 39(6):1010428317711033. PubMed ID: 28639910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
